Don’t see what you’re looking for? Use the search box on MDA’s Quest magazine.
10 short items about the state of ALS science, including stem cells; trials and research models; risk factors; SOD1, TDP43 and C9ORF72 ALS-causing mutations; and more
Posted on Thursday, August 15, 2013 - 04:00, By: Amy Madsen
This roundup of recent amyotrophic lateral sclerosis (ALS) research and clinical trials news includes:
Thanks to promising early safety results, BrainStorm’s phase 1-2 safety trial of adult stem cells has been advanced to a phase 2a dose-escalating trial
Posted on Wednesday, January 9, 2013 - 11:05, By: Amy Madsen
Update (June 10, 2013): BrainStorm announced in a June 10, 2013, press release that enrollment has been completed for the company’s ongoing phase 2a trial of NurOwn adult stem cell therapy in ALS.
NurOwn stem cell technology, currently being tested in Israel, appears safe and seems to improve breathing, swallowing and muscle strength
Posted on Monday, January 23, 2012 - 09:41, By: Amy Madsen
Preliminary data reported Jan. 17, 2012, by BrainStorm Cell Therapeutics demonstrate that the biotechnology company's experimental NurOwn stem cell technology has not caused any significant adverse side effects in a phase 1-2 clinical trial in amyotrophic lateral sclerosis (ALS). In addition,...